Methods for treatment of ocular diseases
Methods and therapeutic treatments of ocular diseases are provided including applying peg-Arginase I to affected eyes. Methods are provided that simultaneously treat inflammation and neovascularization of eyes while promoting healing. Methods are provided to treat lesions or infections of an eye.
1. A method, comprising the steps of:
exogenously applying peg-Arginase I to an eye that has been infected by a drug resistant infectious agent;
simultaneously inhibiting inflammation and neovascularization of corneal tissue of the eye; and
promoting healing of the eye.
2. The method of claim 1 , wherein the drug resistant infectious agent is a virus.
3. The method of claim 2 , wherein the virus is one of HSV-1, HSV-2, CMV, VZV and Adenovirus.
4. The method of claim 2 , wherein the peg-Arginase I inhibits replication of the virus.
5. The method of claim 1 , wherein the drug resistant infectious agent is a bacteria.
6. The method of claim 5 , wherein the bacteria is Chlamydia trachomatis.
7. The method of claim 1 , wherein the peg-Arginase I is part of an ophthalmic formulation.
8. The method of claim 7 , wherein the ophthalmic formulation comprises peg-Arginase I and free peg molecules.
9. The method of claim 8 , wherein the ophthalmic formulation further comprises pH buffers.
10. The method of claim 7 , wherein the ophthalmic formulation is an eye drop.
11. The method of claim 1 , wherein the eye is a mammalian eye.
12. The method of claim 11 , wherein the mammalian eye is a human eye.
13. A therapeutic method to treat an ocular disease, comprising: applying peg-Arginase I to an affected eye;
wherein the peg-Arginase I is part of an ophthalmic formulation; and
wherein the ocular disease is caused by an infection by a drug resistant infectious agent.
14. The therapeutic method of claim 13 , wherein the affected eye presents with at least one of inflammation and neovascularization.
15. The therapeutic method of claim 13 , wherein the drug resistant infectious agent is a virus.
16. The therapeutic method of claim 15 , wherein the peg-Arginase I inhibits replication of the virus.
17. The method of claim 13 , wherein the drug resistant infectious agent is a bacteria.
18. An ocular anti-viral treatment, comprising: applying peg-Arginase I to an infected eye;
wherein the peg-Arginase I is part of an ophthalmic formulation; and
wherein the infected eye has been infected by a drug resistant virus.
19. The treatment of claim 18 , wherein replication of the drug resistant virus is inhibited.
20. The treatment of claim 18 , wherein the drug resistant virus is at least one of HSV-1, HSV-2, CMV, VZV and Adenovirus.
21. A method to prevent ocular neovascularization, comprising:
applying peg-Arginase I to an affected eye;
wherein the peg-Arginase I is part of an ophthalmic formulation; and
wherein the eye that has been infected by a drug resistant infectious agent.
22. The method of claim 21 , wherein the ophthalmic formulation is comprised of peg-Arginase I and free peg molecules.
23. A method to prevent ocular inflammation, comprising:
applying peg-Arginase I to an affected eye;
wherein the peg-Arginase I is part of an ophthalmic formulation; and
wherein the eye that has been infected by a drug resistant infectious agent.
24. The method of claim 23 , wherein the ophthalmic formulation is comprised of peg-Arginase I and free peg molecules.